The prospect is very good for the newly gene-modified T-cells that has so far fully stopped chronic lymphocytic luekemia (CLL) in two volunteers. The remission has continued for already a year since the treatment. We hope that longer remissions will be observed in this new method of gene therapy. Carl June, a gene therapy expert at the University of Pennsylvania, has some much reason to celebrate in the recent albeit small victory in the fight against cancer using a new gene modification technique performed on T-cells. The new method uses a carrier that delivers the new genes to the T-cells. The new genes are designed to begin dictating T-cells to kill cancer cells and multiply. A regiment of mercenary T-cells get reproduced, specifically attacking leukemic cells and eradicating them all. All it takes are three infusions of genetically engineered T-cells. The only drawback so far is the reengineered T-cells' nonspecific targeting of other immune-active blood cells. Still two succ
Groundbreaking science before the news